Study outlines potential new probiotic strain with anti-inflammatory action

By Stephen Daniells

- Last updated on GMT

© sefa ozel / Getty Images
© sefa ozel / Getty Images
A potential probiotic isolated from the rumen of grazing lamb may protect against damage of colon cells and reduce markers of inflammation, says a new study.

French scientists also report that Ligilactobacillus salivarius​ CNCM I-4866 does not contain the genes for antibiotic resistance and mainly produces L-lactate with very little D-lactate. Animal data indicates that L-lactate may alleviate intestinal inflammation, while accumulation of D-lactate can lead to detrimental effects in people with short bowel syndrome.

“Our study has shown that a new strain, L. salivarius​ CNCM I-4866, displays strong anti-inflammatory capacities in vitro​ and in vivo​,” scientists from INRAE at the Université Paris-Saclay wrote in the journal Frontiers in Microbiology.

“Even if further research could be useful to better understand the mechanisms involved or to test this strain on moderate inflammation, CNCM I-4866 is confirmed to be a promising probiotic candidate to alleviate inflammation at the preclinical level on a DNBS model, mimicking IBD and, more specifically, Crohn’s disease.”

Study details

Led by Célia Carbonne and Rebeca Martin, the researchers assessed the safety and efficacy of L. salivarius​ CNCM I-4866, which was as isolated by French company Sorbial. The strain’s potential anti-inflammatory properties were investigated using a mouse model of acute inflammation colitis induced by a chemcical called dinitrobenzene sulfonic acid (DNBS).

Results of the DNMS experiment indicated that the CNCM I-4866 group of mice displayed less intestinal permeability (which is known to increase with inflammation) and to decrease select biomarkers of inflammation.

Additional in vitro​ experiments supported these initial findings, with data showing promotion of an anti-inflammatory effect by decreasing, for example, the production of IL-8, a pro-inflammatory marker.

Moreover, the strain was found to inhibit several intestinal pathogens, such as Escherichia coli, Staphylococcus aureus, Salmonella typhimurium​ and S. enteritidis.

The researchers also investigated the strain’s technical and safety profile, noting that no  antibiotic gene resistance was found, and the strain was “highly resistant to 0.3% of bile salts”.

“Taken together, these results indicate that L. salivarius​ CNCM I-4866 could be a good probiotic candidate for intestinal inflammation, especially with its steady anti-inflammatory profile,” concluded the researchers.

Source: Frontiers in Microbiology
Volume 14 – 2023, doi: 10.3389/fmicb.2023.1270974
Ligilactobacillus salivarius​ CNCM I-4866, a potential probiotic candidate, shows anti-inflammatory properties in vitro​ and in vivo​”
Authors: C. Carbonne, et al.

                                                                                                                                       

Related news

Related products

show more

Embrace the Biotic Edge from Gut to Skin

Embrace the Biotic Edge from Gut to Skin

Content provided by CJ BIO | 08-Nov-2024 | White Paper

Searching for ways to stand out in the market? Dive into our report that analyzes the evolution of the biotics market to identify the key elements driving...

Your Product Innovation Begins Here: Booth 4055

Your Product Innovation Begins Here: Booth 4055

Content provided by Effepharm Ltd | 22-Oct-2024 | Product Brochure

EffePharm will showcase innovative anti-aging solutions, featuring UthPeak™, world’s first self-GRAS approved NMNH, which boosts NAD+ levels by 10X. UthPeak™...

Related suppliers

Follow us

Products

View more

Webinars